Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer

References

• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Hung CF, Yang CK, Ou YC. Urologic cancer in Taiwan. Jpn J Clin Oncol. 2016;46(7):605–609.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Bağcıoğlu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turk J Urol. 2017;43(1):9–13.
   PubMed Web of Science ®Google Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371–380.
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Comperat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461.
   PubMed Web of Science ®Google Scholar
• Choo SH, Nishiyama H, Kitamura H, et al. Practice pattern of non-muscle invasive bladder cancer in Japan, korea and Taiwan: a web-based survey. Int J Urol. 2019;26(12):1121–1127.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk Non-Muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Liem EI, Crezee H, de la Rosette JJ, et al. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia. 2016;32(4):363–373.
   PubMed Web of Science ®Google Scholar
• Juang T, Stauffer PR, Craciunescu OA, et al. Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30(3):176–183.
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, et al. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2014;30(3):171–175.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol. 2019;76(5):639–657.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cheng KS, Craciunescu OI, et al. Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. Med Phys. 2012;39(3):1170–1181.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC. Is CEM43 still a relevant thermal dose parameter for hyperthermia treatment monitoring? Int J Hyperthermia. 2016;32(1):50–62.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute; [cited 2021 Nov 2]. Available from: https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm.
   Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal Meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–95.
   PubMed Web of Science ®Google Scholar
• Volpe A, Racioppi M, D'Agostino D, et al. Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol. 2010;62(2):133–144.
   PubMed Web of Science ®Google Scholar
• van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351–362.
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2018;34(7):988–993.
   PubMed Web of Science ®Google Scholar
• Bryan RT, Collins SI, Daykin MC, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. annals. 2010;92(6):519–524.
   Web of Science ®Google Scholar
• Jancke G, Damm O, Rosell J, et al. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer. Scand J Urol Nephrol. 2008;42(5):417–421.
   PubMed Web of Science ®Google Scholar
• Şanlı Ö, Lotan Y. Alternative therapies in patients with non-muscle invasive bladder cancer. Turk J Urol. 2017;43(4):414–424.
   PubMed Web of Science ®Google Scholar
• Stasi D, Riedl SM. C.: updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol. 2009;27(3):325–330.
   PubMed Web of Science ®Google Scholar
• Parker WP, Smelser W, Lee EK. Utilization and outcomes of radical cystectomy for high-grade non-muscle-invasive bladder cancer in elderly patients. Clin Genitourin Cancer. 2017;2017:2.
   Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): a Phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63–71.
   PubMed Web of Science ®Google Scholar
• Sherar M, Liu FF, Pintilie M, et al. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial. Int J Radiat Oncol Biol Phys. 1997;39(2):371–380.
   PubMed Web of Science ®Google Scholar
• Jeong CW, Jeon HG, Kwak C, et al. Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in korean superficial bladder cancer patients: prospective, randomized study. Cancer Res Treat. 2005;37(1):44–47.
   PubMedGoogle Scholar